nitesh@EGC
Forum Replies Created
-
Posts
-
Hi Shoba,
The agencies (and even different programs within an agency) can vary in regards to their policies about No Cost Extensions, due to a number of different factors. We therefore recommend that companies communicate directly with their Program Director to discuss whether it will be allowable for their situation.
Nitesh.
Hi Shoba,
What you are describing sounds like a small business providing a fee-for-service to the applicant or serving as a sub-contract on the application. In either of these cases, it would be single entity serving as the applicant. Please feel free to clarify further if this does not address your situation.
Nitesh.Hi Shoba,
If the PI has extensive experience in the relevant area that can be clearly described, then this will typically be considered as sufficient. Specific successful outcomes achieved by the PI in the relevant area will be seen as a big positive even in the absence of a PhD.
Best,
Nitesh.Hi Shoba,
The NSF permits foreign collaborators or CROs provided that support is only requested for the US portion of the collaborative effort. NSF may however consider cases where the foreign collaborator provides a unique and essential capability that is not available in the US. You can see NSF’s policy on Foreign Organizations here.
EGC is planning to publish a book for preparing NSF grants. We are anticipating that it will be released in Q1 2021 and available on Amazon.
Best,
NiteshHi Shoba,
You are right – both NSF and NIH have similar interests in some areas.
The NIH is more focused on the application of devices towards specific indications aligned with the mission of a particular Institute/Center. Thus, NIH often supports or even requires clinical trials. On the other hand, NSF generally does not support clinical trials and validation of medical devices.
Hello Jon,
You are right that the Phase I application does not require a commercialization plan. However, reviewers might raise the question of commercialization if they perceive that the proposed product/technology has poor commercial potential or if the market potential is not clear.
You can briefly describe the commercial potential to dispel any concerns, and one paragraph should be sufficient.
Let us know if you have any further questions!
Nitesh.
Hi Rashim,
The NIH makes the payments as cost-reimbursements. You may draw funds in advance, but no more than 3 days before the funds are needed. See the NIH Grants Policy on Payments here: https://grants.nih.gov/grants/policy/nihgps/html5/section_6/6_payment.htm
I hope that helps! Let us know if you have further questions.
Best,
Nitesh.
